UBS Group’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $45.7K | Sell |
3,979
-46,091
| -92% | -$368K | ﹤0.01% | 7621 |
|
|
2026
Q1 | $237K | Buy |
50,070
+48,673
| +3,484% | +$297K | ﹤0.01% | 6541 |
|
|
2025
Q4 | $25.3K | Sell |
1,397
-15,871
| -92% | -$237K | ﹤0.01% | 7628 |
|
|
2025
Q3 | $247K | Buy |
17,268
+8,883
| +106% | +$102K | ﹤0.01% | 6547 |
|
|
2025
Q2 | $64.7K | Sell |
8,385
-15,949
| -66% | -$116K | ﹤0.01% | 7570 |
|
|
2025
Q1 | $145K | Buy |
24,334
+23,500
| +2,818% | +$205K | ﹤0.01% | 6768 |
|
|
2024
Q4 | $11.1K | Buy |
834
+432
| +107% | +$4.55K | ﹤0.01% | 8259 |
|
|
2024
Q3 | $3.27K | Sell |
402
-1
| -0.2% | -$9 | ﹤0.01% | 8295 |
|
|
2024
Q2 | $3.43K | Sell |
403
-3,856
| -91% | -$58K | ﹤0.01% | 8213 |
|
|
2024
Q1 | $73.9K | Sell |
4,259
-143,470
| -97% | -$2.55M | ﹤0.01% | 6347 |
|
|
2023
Q4 | $1.89M | Buy |
147,729
+145,389
| +6,213% | +$3.39M | ﹤0.01% | 3873 |
|
|
2023
Q3 | $86.6K | Buy |
2,340
+285
| +14% | +$12.7K | ﹤0.01% | 5926 |
|
|
2023
Q2 | $82.7K | Sell |
2,055
-11,328
| -85% | -$641K | ﹤0.01% | 6158 |
|
|
2023
Q1 | $970K | Sell |
13,383
-828
| -6% | -$80.3K | ﹤0.01% | 4125 |
|
|
2022
Q4 | $1.17M | Buy |
14,211
+10,778
| +314% | +$1.12M | ﹤0.01% | 3926 |
|
|
2022
Q3 | $325K | Buy |
3,433
+1,800
| +110% | +$202K | ﹤0.01% | 4705 |
|
|
2022
Q2 | $318K | Sell |
1,633
-8,338
| -84% | -$1.36M | ﹤0.01% | 4589 |
|
|
2022
Q1 | $2.32M | Buy |
9,971
+147
| +1% | +$46.8K | ﹤0.01% | 3299 |
|
|
2021
Q4 | $3.87M | Buy |
9,824
+4,411
| +81% | +$1.86M | ﹤0.01% | 3106 |
|
|
2021
Q3 | $2.42M | Buy |
5,413
+4,141
| +326% | +$1.48M | ﹤0.01% | 3414 |
|
|
2021
Q2 | $494K | Sell |
1,272
-2,836
| -69% | -$1.01M | ﹤0.01% | 4743 |
|
|
2021
Q1 | $1.47M | Buy |
4,108
+3,976
| +3,012% | +$1.76M | ﹤0.01% | 3865 |
|
|
2020
Q4 | $65K | Sell |
132
-21
| -14% | -$9.69K | ﹤0.01% | 5959 |
|
|
2020
Q3 | $49K | Sell |
153
-46
| -23% | -$15.7K | ﹤0.01% | 5662 |
|
|
2020
Q2 | $72K | Sell |
199
-199
| -50% | -$50.3K | ﹤0.01% | 5564 |
|
|
2020
Q1 | $85K | Sell |
398
-1,110
| -74% | -$352K | ﹤0.01% | 5424 |
|
|
2019
Q4 | $621K | Sell |
1,508
-251
| -14% | -$86.5K | ﹤0.01% | 4640 |
|
|
2019
Q3 | $621K | Buy |
1,759
+1,619
| +1,156% | +$604K | ﹤0.01% | 4375 |
|
|
2019
Q2 | $70K | Buy |
140
+74
| +112% | +$52.2K | ﹤0.01% | 5634 |
|
|
2019
Q1 | $66K | Sell |
66
-27
| -29% | -$25.1K | ﹤0.01% | 5351 |
|
|
2018
Q4 | $80K | Sell |
93
-643
| -87% | -$597K | ﹤0.01% | 5725 |
|
|
2018
Q3 | $760K | Buy |
736
+703
| +2,130% | +$687K | ﹤0.01% | 4088 |
|
|
2018
Q2 | $30K | Sell |
33
-4,086
| -99% | -$4.39M | ﹤0.01% | 6375 |
|
|
2018
Q1 | $4.02M | Buy |
4,119
+4,068
| +7,976% | +$3.71M | ﹤0.01% | 2511 |
|
|
2017
Q4 | $23K | Buy |
51
+9
| +21% | +$3.32K | ﹤0.01% | 6440 |
|
|
2017
Q3 | $17K | Buy |
42
+41
| +4,100% | +$15.5K | ﹤0.01% | 6560 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7648 |
|
|
2017
Q1 | $0 | Sell |
1
-336
| -100% | -$139K | ﹤0.01% | 7625 |
|
|
2016
Q4 | $120K | Buy |
337
+61
| +22% | +$25.8K | ﹤0.01% | 5162 |
|
|
2016
Q3 | $148K | Sell |
276
-25
| -8% | -$13.6K | ﹤0.01% | 4744 |
|
|
2016
Q2 | $169K | Buy |
301
+14
| +5% | +$6.72K | ﹤0.01% | 4651 |
|
|
2016
Q1 | $136K | Sell |
287
-1,115
| -80% | -$502K | ﹤0.01% | 4759 |
|
|
2015
Q4 | $925K | Buy |
1,402
+1,255
| +854% | +$949K | ﹤0.01% | 3466 |
|
|
2015
Q3 | $116K | Buy |
147
+28
| +24% | +$34.1K | ﹤0.01% | 5099 |
|
|
2015
Q2 | $158K | Buy |
119
+79
| +198% | +$90.6K | ﹤0.01% | 5065 |
|
|
2015
Q1 | $42K | Sell |
40
-4
| -9% | -$2.64K | ﹤0.01% | 6213 |
|
|
2014
Q4 | $29K | Buy |
+44
| New | +$26.9K | ﹤0.01% | 7135 |
|
Other funds holding ATRA
VCM
SCA
VFT
UBS Group's ATRA Position: Q2 2026 in Review
UBS Group reduced its Atara Biotherapeutics (ATRA) stake by 92% in Q2 2026, selling an estimated $368K and leaving 3,979 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7621.
UBS Group first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $4.02M in Q1 2018. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- UBS Group held 3,979 shares of Atara Biotherapeutics worth $45.7K as of Q2 2026.
- UBS Group sold 46,091 Atara Biotherapeutics shares in Q2 2026, an estimated $368K.
- Atara Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7621 holding.
- UBS Group first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Atara Biotherapeutics position peaked at $4.02M in Q1 2018.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.